249 related articles for article (PubMed ID: 31922884)
1. Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present).
Zhou H; Wang Y; You Q; Jiang Z
Expert Opin Ther Pat; 2020 Mar; 30(3):209-225. PubMed ID: 31922884
[No Abstract] [Full Text] [Related]
2. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development.
Robledinos-Antón N; Fernández-Ginés R; Manda G; Cuadrado A
Oxid Med Cell Longev; 2019; 2019():9372182. PubMed ID: 31396308
[TBL] [Abstract][Full Text] [Related]
3. An updated patent review of Nrf2 activators (2020-present).
Zhao Z; Dong R; Cui K; You Q; Jiang Z
Expert Opin Ther Pat; 2023 Jan; 33(1):29-49. PubMed ID: 36800917
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).
Sun H; Zhu J; Lin H; Gu K; Feng F
Expert Opin Ther Pat; 2017 Jul; 27(7):763-785. PubMed ID: 28454500
[TBL] [Abstract][Full Text] [Related]
5. KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.
Crisman E; Duarte P; Dauden E; Cuadrado A; Rodríguez-Franco MI; López MG; León R
Med Res Rev; 2023 Jan; 43(1):237-287. PubMed ID: 36086898
[TBL] [Abstract][Full Text] [Related]
6. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
7. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
8. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Lu MC; Ji JA; Jiang ZY; You QD
Med Res Rev; 2016 Sep; 36(5):924-63. PubMed ID: 27192495
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
10. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the Clinical Development of NRF2-Targeting Drugs.
Lastra D; Fernández-Ginés R; Manda G; Cuadrado A
Handb Exp Pharmacol; 2021; 264():93-141. PubMed ID: 32776282
[TBL] [Abstract][Full Text] [Related]
12. Discovery of benzo[g]indoles as a novel class of non-covalent Keap1-Nrf2 protein-protein interaction inhibitor.
Yasuda D; Yuasa A; Obata R; Nakajima M; Takahashi K; Ohe T; Ichimura Y; Komatsu M; Yamamoto M; Imamura R; Kojima H; Okabe T; Nagano T; Mashino T
Bioorg Med Chem Lett; 2017 Nov; 27(22):5006-5009. PubMed ID: 29037947
[TBL] [Abstract][Full Text] [Related]
13. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents.
Abed DA; Goldstein M; Albanyan H; Jin H; Hu L
Acta Pharm Sin B; 2015 Jul; 5(4):285-99. PubMed ID: 26579458
[TBL] [Abstract][Full Text] [Related]
14. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors.
Mou Y; Wen S; Li YX; Gao XX; Zhang X; Jiang ZY
Eur J Med Chem; 2020 Sep; 202():112532. PubMed ID: 32668381
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
17. An Overview of the Advantages of KEAP1-NRF2 System Activation During Inflammatory Disease Treatment.
Keleku-Lukwete N; Suzuki M; Yamamoto M
Antioxid Redox Signal; 2018 Dec; 29(17):1746-1755. PubMed ID: 28899203
[TBL] [Abstract][Full Text] [Related]
18. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
19. Emerging Screening Approaches in the Development of Nrf2-Keap1 Protein-Protein Interaction Inhibitors.
Leung CH; Zhang JT; Yang GJ; Liu H; Han QB; Ma DL
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31509940
[TBL] [Abstract][Full Text] [Related]
20. Identification of compounds that inhibit the binding of Keap1a/Keap1b Kelch DGR domain with Nrf2 ETGE/DLG motifs in zebrafish.
Raghunath A; Nagarajan R; Sundarraj K; Palanisamy K; Perumal E
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):259-270. PubMed ID: 30861618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]